^
Association details:
| Biomarker: | EGFR exon 19 insertion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of EGFR-TKI sequential therapy in patients with EGFR exon 19 insertion-positive non-small-cell lung cancer: A case report
Excerpt:
...a case of lung adenocarcinoma with rare EGFR exon 19 insertion benefitting from afatinib therapy.
DOI:
10.12998/wjcc.v10.i6.1883
Source:
Title:
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
Excerpt:
The resulting mutant cell lines were then assessed for sensitivity to TKIs using gefitinib (reversible EGFR-TKI) and afatinib (irreversible EGFR-TKI).... EGFR exon 19 insertions were introduced into Ba/F3 cells to assess oncogenicity and in vitro sensitivity to EGFR TKIs. The Ba/F3 cells transfected with exon 19 insertions were found to be sensitive to both TKIs, similar to Ba/F3 cells harboring the common EGFR exon 19 deletion (E746_A750del) (Figure 2A).
DOI:
10.1158/1078-0432.CCR-11-2361
